EASD 2019 — Semaglutide improves glycemic control and BMI better than liraglutide in T2D


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Semaglutide, a glucagon-like peptide-1 analogue, was associated with better glycemic control and greater reductions in body weight compared with liraglutide in adult patients with type 2 diabetes (T2D).

Why this matters

  • Patients with T2D have difficulty achieving optimal control of blood glucose if they are also overweight or obese.

Study design

  • Adults with T2D who were taking 1-3 oral glucose-lowering drugs were randomly assigned:
    • Once-weekly semaglutide 1.0 mg (n=290).
    • Once-daily liraglutide 1.2 mg (n=287).
  • Change in HbA1c from baseline to week 30 comprised the primary efficacy endpoint.
  • Confirmatory secondary endpoint was change in body weight at week 30.
  • Funding: Novo Nordisk.

Key results

  • Compared with mean baseline HbA1c (8.2%), treatment with semaglutide was associated with a greater percentage-point reduction in HbA1c by week 30 vs liraglutide (1.7%-point change vs 1.0%-point change; estimated treatment difference [ETD], −0.69% point; 95% CI, −0.82 to −0.56; P<.0001>
  • A greater proportion of semaglutide-treated patients achieved HbA1c
  • More patients in the semaglutide arm also achieved weight loss of ≥5% (55.9% vs 17.7%; OR, 5.89; P<.0001 and vs or p>
  • Slightly more adverse events were observed in the semaglutide group (70.6% vs 66.2%).

Limitations

  • Lack of participant lifestyle data.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit